Cite
HARVARD Citation
Morita‐Fujita, M. et al. (2022). Adult patients with Ph+ ALL benefit from conditioning regimen of medium‐dose VP16 plus CY/TBI. Hematological oncology. 40 (5), pp. 1041-1055. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Morita‐Fujita, M. et al. (2022). Adult patients with Ph+ ALL benefit from conditioning regimen of medium‐dose VP16 plus CY/TBI. Hematological oncology. 40 (5), pp. 1041-1055. [Online].